Palette Life Sciences
Finding new ways to improve patient care through research and innovation.
| SEK | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 89 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | (120 %) | (99 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Palette Life Sciences, now a part of Teleflex, operates as a fully integrated medical device company specializing in treatments for urological, urogynecological, and colorectal disorders, as well as radiotherapy and interventional oncology procedures.
The company was co-founded by Per Langö, who also served as CEO, and Travis Gay, the Chief Commercial Officer. Langö brought over two decades of experience from leadership roles at MedTech firms like Q-Med, Galderma, and Nestlé Skin Health, shaping the company's focus on commercialization and market development. The formation of Palette involved licensing the core technology platform and three key assets from Nestlé Skin Health, with strategic guidance from Back Bay Life Science Advisors. A significant milestone in the company's journey was its acquisition by Teleflex, a leading global provider of medical technologies. The definitive agreement was announced in July 2023 and completed in October 2023 for an upfront cash payment of $600 million, with up to an additional $50 million contingent on commercial milestones. At the time, Palette Life Sciences was projected to generate approximately $56 million in net sales for 2023.
Palette’s business model revolves around developing and commercializing minimally invasive treatment options that utilize its core technology: Non-Animal Stabilized Hyaluronic Acid (NASHA). This technology has a proven safety and efficacy profile from over two decades of use in millions of medical procedures. The company sells its products to physicians, specialists, and healthcare providers globally. Key products include Barrigel®, a biodegradable rectal spacer designed to reduce radiation exposure to the rectum during prostate cancer therapy. It received FDA clearance in 2022 and is also available in Europe and Australia. The portfolio also features Deflux®, an injectable treatment for pediatric vesicoureteral reflux (VUR), and Solesta®, an injectable for fecal incontinence.
Keywords: Palette Life Sciences, Teleflex, medical devices, urology, urogynecology, interventional oncology, colorectal conditions, Non-Animal Stabilized Hyaluronic Acid, NASHA, Per Langö, Travis Gay, Barrigel, rectal spacer, prostate cancer radiotherapy, Deflux, vesicoureteral reflux, Solesta, fecal incontinence, injectable treatment, minimally invasive, medtech acquisition, hyaluronic acid gel